B. Riley raised the firm’s price target on Wave Life Sciences (WVE) to $37 from $19 and keeps a Buy rating on the shares reflecting strategic value and projected obesity-related revenues. Despite minimal absolute weight loss at the low dose of WVE-007, preclinical modeling suggests continued efficacy, and upcoming obesity and RNA-editing catalysts are expected to provide tailwinds through 2026, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WVE: